| Filed On | Filing |
|---|---|
| 05 Aug 2021 |
8-K/A: Financial Statements and Exhibits
The accompanying notes are an integral part of these unaudited condensed financial statements. |
| 31 Jul 2020 |
8-K/A: Completion of Acquisition or Disposition of Assets
We are a clinical-stage biopharmaceutical company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. Our immuno-oncology product candidates include... |
Loading...